Abciximab: a reappraisal of its use in coronary care

References

• ACC/AHA2007ACC/AHA 2007. Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarctionJ Am Coll Cardiol50e117692738
   PubMed Web of Science ®Google Scholar
• AntoniucciDRodriguezAHempelA2003A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarctionJ Am Coll Cardiol42187914662245
   PubMed Web of Science ®Google Scholar
• AsterRH2005Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitorsChest12753S15706031
   PubMed Web of Science ®Google Scholar
• AtwaterBDRoeMTMahaffeyKW2005Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes. A review and guide to patient selectionDrugs6531315669877
   PubMed Web of Science ®Google Scholar
• BatchelorWBTollesonTRHuangY2002Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes. The COMPARE TrialCirculation106147012234950
   PubMed Web of Science ®Google Scholar
• BertrandOFDe LarochellièreRRodés-CabauJ2006A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantationCirculation114263617145988
   PubMed Web of Science ®Google Scholar
• BologneseLFalsiniGLiistroF2005Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trialJ Am Coll Cardiol4752216458130
   PubMed Web of Science ®Google Scholar
• BraunwaldEAntmanEMBeasleyJW2002ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina)J Am Coll Cardiol40136612383588
   PubMed Web of Science ®Google Scholar
• BurzottaFRomagnoliETraniC2003Intracoronary administration of abciximab acutely increases flow through culprit vessels of patients with acute coronary syndromes undergoing percutaneous coronary interventionCirculation108e13814610001
   PubMed Web of Science ®Google Scholar
• CampoGValgimigliMGemmatiD2006Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY studyJ Am Coll Cardiol48217817161242
   PubMed Web of Science ®Google Scholar
• DanziGBSesanaMCapuanoC2004Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular functionAm J Cardiol943515219505
   PubMed Web of Science ®Google Scholar
• De LucaGSuryapranataHStoneGW2006Relationship between patient’s risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: A meta-regression analysis of randomized trialsJ Am Coll Cardiol4768516458158
   PubMed Web of Science ®Google Scholar
• ErnstNSuryapranataHMiedemaK2004Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarctionJ Am Coll Cardiol44118715364318
   PubMed Web of Science ®Google Scholar
• GowdaRMKhanIAVasavadaBC2004Therapeutics of Platelet Glycoprotein IIb/IIIa Receptor AntagonismAm J Therapeutics11302
   PubMedGoogle Scholar
• HongYJJeongMHKimW2004Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteriesAm J Cardiol94105015476624
   PubMed Web of Science ®Google Scholar
• KabbaniSSWatkinsMWAshikagaT2001Platelet reactivity characterized prospectively. A determinant of outcome 90 days after percutaneous coronary interventionCirculation10418111447083
   PubMed Web of Science ®Google Scholar
• KabbaniSSWatkinsMWAshikagaT2003Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year laterAm J Cardiol9187612667577
   PubMed Web of Science ®Google Scholar
• KastratiAMehilliJNeumannFJ2006Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 Randomized TrialJAMA295E1
   Web of Science ®Google Scholar
• KastratiAMehilliJSchuhlenH2004A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrelN Engl J Med35023214724302
   PubMed Web of Science ®Google Scholar
• KimWJeongMHKimKH2006The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarctionJ Am Coll Cardiol4793316516074
   PubMed Web of Science ®Google Scholar
• MagerDEMascelliMAKleimanNS2003Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplastyJ Pharma Exp Ther307969
   PubMed Web of Science ®Google Scholar
• MarmurJDMitreCABarnathanE2006Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trialAm Heart J15287617070148
   PubMed Web of Science ®Google Scholar
• MarmurJDPoludasuSAgarwalA2006Bolus-only platelet glyco-protein IIb-IIIa inhibition during percutaneous coronary interventionJ Invasive Cardiol1852117090813
   PubMedGoogle Scholar
• MatetzkySShenkmanBGuettaV2004Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarctionCirculation109317115184279
   PubMed Web of Science ®Google Scholar
• MontalescotGAntoniucciDKastratiA2007Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients data with long-term follow-upEur Heart J2844317251257
   PubMed Web of Science ®Google Scholar
• MontalescotGBarraganPWittenbergO2001Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarctionN Engl J Med344189511419426
   PubMed Web of Science ®Google Scholar
• NeumannFJKastratiASchmittC2000Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarctionJ Am Coll Cardiol3591510732888
   PubMed Web of Science ®Google Scholar
• RaveendranGTingHHBestPJ2007Eptifibatide vs. abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarctionMayo Clin Proc8219617290727
   PubMed Web of Science ®Google Scholar
• SchneiderDJHerrmannHCLakkisN2002Enhanced early inhibition of platelet aggregation with an increased bolus of tirofibanAm J Cardiol90142112480064
   PubMed Web of Science ®Google Scholar
• SchrorKWeberAA2003Comparative Pharmacology of GP IIb/IIIa AntagonistsJ Thromb Thrombolysis157114618072
   PubMed Web of Science ®Google Scholar
• SchweigerMJChangeziHUNaglieri-PrescodD2003Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary interventionClin Ther2522512637122
   PubMed Web of Science ®Google Scholar
• SilvaMAGandhiPJ2004Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?J Clin PharmTher29497
   Google Scholar
• StoneGWMcLaurinBTCoxDA2006Bivalirudin for patients with acute coronary syndromesN Engl J Med355220317124018
   PubMed Web of Science ®Google Scholar
• StoneGWBertrandMEMosesJW2006Routine upstream initiation vs. deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. the ACUITY-TIMING trialJ Am Med Ass297591
   Web of Science ®Google Scholar
• The CAPTURE Investigators1997Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyLancet34914299164316
   PubMed Web of Science ®Google Scholar
• The EPIC Investigators1994Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplastyN Engl J Med3309568121459
   PubMed Web of Science ®Google Scholar
• The EPILOG Investigators1997Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularizationN Engl J Med33616899182212
   PubMed Web of Science ®Google Scholar
• The EPISTENT Investigators1998Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeLancet352879672272
   PubMed Web of Science ®Google Scholar
• The GUSTO IV-ACS Investigators2001Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialLancet357191511425411
   PubMed Web of Science ®Google Scholar
• The PRISM PLUS Investigators1998Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarctionN Engl J Med33814889599103
   PubMed Web of Science ®Google Scholar
• The PURSUIT Trial Investigators1998Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromesN Engl J Med3394369705684
   PubMed Web of Science ®Google Scholar
• The RESTORE Investigators1997Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplastyCirculation9614459315530
   PubMed Web of Science ®Google Scholar
• Task force for percutaneous coronary intervention of the european society of cardiology2005Guidelines for percutaneous coronary interventionEur Heart J2680415769784
   PubMed Web of Science ®Google Scholar
• Task force for diagnosis and treatment of non ST-segment elavation acute coronary syndromes2007Guidelines for the diagnosis and treatment of non ST-segment elavation acute coronary syndromesEur Heart J28159817569677
   PubMed Web of Science ®Google Scholar
• TopolEMoliternoDHerrmannH2001Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abcix imab, for the prevention of ischemic events with percutaneous coronary revascularizationN Engl J Med344188811419425
   PubMed Web of Science ®Google Scholar
• TopolEJByzovaTVPlowEF1999Platelet GPIIb-IIIa blockersLancet3532279923894
   PubMed Web of Science ®Google Scholar
• ValgimigliMPercocoGMalaguttiP2005Tirofiban and sirolimuseluting stent vs. abciximab and bare-metal stent for acute myocardial infarction: a randomized trialJAMA293210915870414
   PubMed Web of Science ®Google Scholar
• WöhrleJGrebeOCNusserT2003Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplastyCirculation107184012682003
   PubMed Web of Science ®Google Scholar